#$%^&*AU2017200543B220181115.pdf#####Abstract AU2017200543 The present invention relates to a method of mitigating in a mammal one or more symptoms associated with a disease characterized by amyloid, in particular beta-amyloid, deposits in the brain, or delaying or preventing the onset of said symptoms, said method comprising: administering one or more compounds selected from defined tropinol esters and related quinuclidine esters. Said amyloidogenic diseases include Alzheimer's disease, cognitive impairment, age-related macular degeneration (AMD), cerebrovascular dementia, Parkinson's disease, Huntington's disease, and cerebral amyloid angiopathy. The present invention further relates to a method of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway as characterized by increasing sAPPa and/or the sAPPa/A42 ratio in a mammal, and a method of inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) in a mammal, via the administration of said defined tropinol esters and related quinuclidine ester compoundsWO 2013/019901 PCT/US2012/049223 1/7 AcHNI S bt Me (R) &/ (S e AW40 00 MK AAN HO Various amino adid esters both & 0 Fig. IA 00/ AcHH HN 0 04 (R' 0 &t~e Fig. l B